GENEVA — The World Health Organization has officially welcomed initial clinical trial results from the United Kingdom demonstrating that the widely used corticosteroid dexamethasone can be lifesaving for patients suffering from critical forms of COVID-19. According to preliminary findings shared directly with the global health agency, the treatment significantly reduces mortality rates among hospitalized individuals with severe respiratory complications, marking a major milestone in the global therapeutic response to the pandemic.
For patients who are severely ill and placed on mechanical ventilators, the preliminary data shows that dexamethasone reduces mortality by approximately one third. Meanwhile, for patients whose conditions are less severe but still require supplemental oxygen support, the treatment cuts mortality by about one fifth. These findings represent a substantial breakthrough in acute clinical care, offering a desperately needed therapeutic option for healthcare providers struggling to manage the most vulnerable coronavirus patients.
However, health authorities and researchers have underscored a critical boundary regarding the drug’s efficacy. The pronounced survival benefits were observed strictly in patients who are seriously ill with COVID-19. The therapeutic effect was notably absent in individuals exhibiting milder forms of the disease, indicating that the medication should be reserved for advanced stages of clinical intervention rather than administered as a broad prophylactic or early-stage outpatient treatment.
Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, praised the findings during a public briefing on the development. This is the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support, Dr Tedros noted, emphasizing the significance of the achievement. This is great news and I congratulate the Government of the UK, the University of Oxford, and the many hospitals and patients in the UK who have contributed to this lifesaving scientific breakthrough.
Dexamethasone is not a newly engineered pharmaceutical compound designed specifically for the novel coronavirus. Instead, it is a conventional steroid that has been utilized in global medical practice since the 1960s to reduce inflammation across a broad spectrum of medical conditions, ranging from severe inflammatory disorders to certain forms of cancer. Its long-standing clinical profile means that the medical community already possesses extensive familiarity with its pharmacological properties, dosage guidelines, and potential side effects.
Furthermore, the drug’s widespread availability and economic accessibility distinguish it from many experimental or newly developed antiviral therapies. Dexamethasone has been listed on the World Health Organization Model List of Essential Medicines since 1977 in multiple pharmaceutical formulations. Because it is currently off-patent, it is affordably and readily available in the vast majority of countries around the world, raising hopes that the newfound treatment protocol can be implemented swiftly in both high-income nations and resource-limited settings alike.
Following the initial release of these insights, researchers involved in the UK trials are preparing to publish a comprehensive data analysis in the coming days. The World Health Organization has announced that it will actively coordinate a formal meta-analysis once the complete dataset is available. This rigorous statistical review aims to increase the global scientific community’s overall understanding of the intervention, examining how the drug interacts with various patient profiles, underlying health conditions, and concurrent therapies.
In response to the evolving scientific landscape, the World Health Organization confirmed that its official clinical guidance will be updated to reflect precise recommendations on how and when the drug should be administered to COVID-19 patients. Clinical guidelines must carefully calibrate dosage, timing, and patient selection criteria to ensure maximum therapeutic benefit while mitigating any potential risks associated with prolonged corticosteroid use, such as secondary infections or elevated blood glucose levels.
Today’s announcement builds directly upon strategic groundwork laid earlier in the year. The findings trace their institutional lineage back to the World Health Organization Research and Development Blueprint meeting, which convened in Geneva in mid-February. That high-level gathering was specifically organized to accelerate health technologies, diagnostics, therapeutics, and vaccines for COVID-19. During those foundational discussions, prioritized research into the clinical utility of steroids was highlighted as an urgent objective for the international research community.
The success of the UK trial reinforces the profound importance of large-scale, randomized controlled trials. Public health experts have repeatedly emphasized that only robustly designed clinical studies can produce the high-quality, actionable evidence required to alter clinical practice standards safely and effectively during a fast-moving global health crisis. Without such randomized data, physicians are often left relying on anecdotal observations or weaker observational studies, which can lead to conflicting treatment protocols.
Looking ahead, the World Health Organization has pledged to continue working hand in hand with international partners, academic institutions, and regulatory bodies. The goal remains steadfast: to further develop, evaluate, and distribute lifesaving therapeutics and vaccines to tackle COVID-19 on a global scale. This collaborative effort continues to operate under the umbrella of broader international initiatives, including the Access to COVID-10 Tools Accelerator, which seeks to ensure equitable access to essential medical countermeasures for populations everywhere.
As the medical community awaits the full publication of the trial data, the integration of dexamethasone into standard critical care protocols represents a tangible step forward in the ongoing global effort to reduce mortality rates and alleviate the immense burden placed on intensive care units worldwide.
Fadela Chaib, Communications Officer and Spokesperson for the World Health Organization, handled communications regarding the announcement from Geneva.
